Results 141 to 150 of about 42,317 (192)

Long‐Term Persistence and Treatment Changes of Antihypertensive Therapy: A 5‐Year Cohort Study

Basic &Clinical Pharmacology &Toxicology, Volume 139, Issue 3, September 2026.
ABSTRACT Aim To estimate persistence with antihypertensive therapy (AHT) and describe treatment changes and associated factors among persistent patients over 5 years. Methods We conducted a longitudinal cohort study using the IADB.nl pharmacy database in the Netherlands, including adults who initiated AHT between 2014 and 2018 after a 2‐year washout ...
Amal Asiri, Sumaira Mubarik, Jens H. J. Bos, Catharina C. M. Schuiling‐Veninga, Eelko Hak, Katja Taxis   +5 more
wiley   +1 more source

Genetically predicted benign prostate hyperplasia causally affects prostate cancer: a two-sample Mendelian randomization. [PDF]

Transl Androl Urol
Huang H, Hu Z, Chen Z, Zhang Y, Yang C.
europepmc   +1 more source

Phloretin in Benign Prostate Hyperplasia and Prostate Cancer: A Contemporary Systematic Review. [PDF]

Life (Basel), 2022
Yang CH, Ou YC, Lin CC, Lin YS, Tung MC, Yu CC, Lin JT, Wen CY.   +7 more
europepmc   +1 more source

The Four‐Bladder Neck Implant Technique on Early Outcomes After Prostatic Urethral Lift: A Japanese Prospective Single‐Center Study

International Journal of Urology, Volume 33, Issue 9, September 2026.
ABSTRACT Objectives Outcomes after prostatic urethral lift (PUL) may vary depending on implant position and bladder neck remodeling strategy. We evaluated the impact of bladder‐neck‐focused implant density using a four‐bladder neck implant technique on early postoperative urinary outcomes.
Go Anan, Yosuke Fujishima, Hidero Minami, Takuro Ishii, Kanya Kaga   +4 more
wiley   +1 more source

Dehydroepiandrosterone Decline in Aging Males as a Predictor of Erectile Dysfunction and Mood Disorders in Patients With Benign Prostate Hyperplasia Undergoing Dutasteride Treatment. [PDF]

Am J Mens Health
Glavinov MS, Tahir S, Arsov S.
europepmc   +1 more source

Impact of Clinicopathological and Institutional Factors on the Clinical Courses of Patients With Localized Prostate Cancer Initially Managed by Active Surveillance: An Analysis of Nationwide Real‐World Data From Japan

International Journal of Urology, Volume 33, Issue 9, September 2026.
ABSTRACT Objectives To investigate active surveillance (AS) continuation rates and associated clinical and institutional factors in Japanese patients with localized prostate cancer. Methods We retrospectively analyzed 989 patients with localized prostate cancer from 92 institutions who initiated AS between 2016 and 2018.
Mizuki Onozawa, Masaki Shiota, Taketo Kawai, Shinichi Sakamoto, Yoshiyuki Yamamoto, Satoru Taguchi, Yasuhide Kitagawa, Tohru Nakagawa, Shiro Hinotsu, Jun Miyazaki, Haruki Kume, Japan Study Group of Prostate Cancer (J‐CaP)   +11 more
wiley   +1 more source

Efficacy, feasibility, and safety of aquablation after previous urolift treatment of lower urinary tract symptoms secondary to benign prostate hyperplasia: a retrospective cohort study. [PDF]

World J Urol
Darwazeh H, Ng KL, Barber N.
europepmc   +1 more source

Do the treatment selection factors emphasized in clinical guidelines—Chronic kidney disease, cardiovascular disease, and heart failure—contribute to the risk of urinary tract infections during the administration of sodium‐glucose cotransporter‐2 inhibitors?

Journal of Diabetes Investigation, Volume 17, Issue 9, Page 1489-1498, September 2026.
ABSTRACT Aims/Introduction Sodium‐glucose cotransporter‐2 inhibitors (SGLT2Is) are recommended in Japan for patients with cardiovascular disease (CVD), heart failure (HF), or chronic kidney disease (CKD) due to their organ‐protective effects, leading to increased use in high‐risk populations.
Takuma Koinuma, Manato Yoshida, Manabu Akazawa   +2 more
wiley   +1 more source

Comparison of outcome for holmium laser enucleation prostate and Rezum system in benign prostate hyperplasia: a matched pair analysis. [PDF]

World J Urol
Özkaptan O, Sevinç C, Çanakcı C, Aydoğan TB, Türkyılmaz O, Mert MS, Çubuk A.   +6 more
europepmc   +1 more source

Guideline for Medication Management of Distressing Symptoms in Older Patients Receiving End‐of‐Life Palliative Care

Journal of Evidence-Based Medicine, Volume 19, Issue 3, September 2026.
ABSTRACT Older patients receiving end‐of‐life palliative care often present with multiple geriatric syndromes, frailty, and comorbid symptom burden, resulting in a high risk of medication‐related harm. This guideline focuses on pharmacological management of distressing symptoms in older patients receiving end‐of‐life or hospice‐oriented palliative care,
Daiping Li, Yanwu Yang, Yan Zhang, Jirong Yue, Birong Dong, Meiling Ge, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University   +7 more
wiley   +1 more source